These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36804202)

  • 1. The Glycosylated
    Miyazaki K; Kishimoto H; Kobayashi H; Suzuki A; Higuchi K; Shirasaka Y; Inoue K
    Mol Pharmacol; 2023 Mar; 103(3):166-175. PubMed ID: 36804202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in MUC1 resistance to chemotherapy in pancreatic cancer.
    Yao Y; Fan D
    J Chemother; 2024 Oct; 36(6):449-456. PubMed ID: 38006297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Transmembrane Mucin MUC1 Facilitates β1-Integrin-Mediated Bacterial Invasion.
    Li X; Wubbolts RW; Bleumink-Pluym NMC; van Putten JPM; Strijbis K
    mBio; 2021 Apr; 12(2):. PubMed ID: 33824202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.
    Jin W; Liao X; Lv Y; Pang Z; Wang Y; Li Q; Liao Y; Ye Q; Chen G; Zhao K; Huang L
    Cell Death Dis; 2017 Aug; 8(8):e2980. PubMed ID: 28796259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
    Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
    Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
    Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
    Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents.
    Farahmand L; Merikhian P; Jalili N; Darvishi B; Majidzadeh-A K
    Curr Cancer Drug Targets; 2018; 18(8):737-748. PubMed ID: 28669345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylated modification of MUC1 maybe a new target to promote drug sensitivity and efficacy for breast cancer chemotherapy.
    Xi X; Wang J; Qin Y; Huang W; You Y; Zhan J
    Cell Death Dis; 2022 Aug; 13(8):708. PubMed ID: 35970845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
    Uchida Y; Raina D; Kharbanda S; Kufe D
    Cancer Biol Ther; 2013 Feb; 14(2):127-34. PubMed ID: 23114713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.
    Xu X; Wells A; Padilla MT; Kato K; Kim KC; Lin Y
    Carcinogenesis; 2014 Nov; 35(11):2457-66. PubMed ID: 25085901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma.
    Cai BL; Xu XF; Fu SM; Shen LL; Zhang J; Guan SM; Wu JZ
    Oral Oncol; 2011 Dec; 47(12):1134-40. PubMed ID: 21903448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
    Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
    Song S; Wientjes MG; Gan Y; Au JL
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8658-63. PubMed ID: 10890892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
    Lehuédé C; Li X; Dauvillier S; Vaysse C; Franchet C; Clement E; Esteve D; Longué M; Chaltiel L; Le Gonidec S; Lazar I; Geneste A; Dumontet C; Valet P; Nieto L; Fallone F; Muller C
    Breast Cancer Res; 2019 Jan; 21(1):7. PubMed ID: 30654824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cell adaptation to chemotherapy.
    Di Nicolantonio F; Mercer SJ; Knight LA; Gabriel FG; Whitehouse PA; Sharma S; Fernando A; Glaysher S; Di Palma S; Johnson P; Somers SS; Toh S; Higgins B; Lamont A; Gulliford T; Hurren J; Yiangou C; Cree IA
    BMC Cancer; 2005 Jul; 5():78. PubMed ID: 16026610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress.
    Chen Q; Li D; Ren J; Li C; Xiao ZX
    Biochem Biophys Res Commun; 2013 Oct; 440(1):179-83. PubMed ID: 24055030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.